Sergio Cifuentes Canaval, Cancer Research Project Manager at
“Exciting news from the ALINA trial! Alectinib, an oral tyrosine kinase inhibitor, has shown remarkable results in resected ALK-positive NSCLC. Patients receiving alectinib had a 76% lower risk of disease recurrence or death compared to chemotherapy. Promising outcomes with a low-grade safety profile.
Wu Y-L et al. have just released the results of a groundbreaking preplanned interim analysis from the **ALINA trial**.
- Phase III, patients with resected ALK NSCLC
- 257 patients stages IB, II, or IIIA
- Randomly 1:1 to Alectinib 2 years vs Platinum-Based Chemotherapy for four cycles
- Primary Endpoint: DFS
- Median follow-up of 27.8 months, alectinib with a 76% lower risk of disease recurrence or death compared to chemotherapy
Implications:
- Alectinib represents a paradigm shift in the battle against early-stage, resectable ALK-positive lung cancer.
- It not only improves patient outcomes but also reduces the risk of disease recurrence.”